Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tilogotamab (GEN-1029) is an enhanced hexameric mixture of two agonistic antibodies that bind to distinct epitopes on death receptor type 5 (DR5), specifically activating it. This compound is utilized in the research of multiple myeloma (MM) [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | Inquiry | Inquiry | |
5 mg | Inquiry | Inquiry |
Description | Tilogotamab (GEN-1029) is an enhanced hexameric mixture of two agonistic antibodies that bind to distinct epitopes on death receptor type 5 (DR5), specifically activating it. This compound is utilized in the research of multiple myeloma (MM) [1]. |
In vivo | Tilogotamab at a concentration of 20 μg/mL for 24 hours exhibits potent cytotoxicity against primary MM cells [1]. Tilogotamab is a mixture of two non-competitive DR5-specific monoclonal immunoglobulin G1 (IgG1) antibodies, each featuring an E430G mutation in the Fc domain. This mutation enhances Fc-Fc interactions, leading to antibody hexamerization and subsequent FcγR-independent clustering of DR5 molecules [1]. |
Synonyms | GEN-1029, HexaBody-DR5/DR5, Hx-DR5-01/05 |
Molecular Weight | N/A |
CAS No. | 2109731-10-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tilogotamab 2109731-10-2 GEN-1029 HexaBody-DR5/DR5 Hx-DR5-01/05 inhibitor inhibit